Physician profile
John G Youssef
NPI 1467595975
$10,809.94
in general payments reported to CMS, 2019-2025
29 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2022: $268 · 2023: $2,698 · 2024: $6,381 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,172 · Food and Beverage: $3,198 · Travel and Lodging: $1,560 · Consulting Fee: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,172.42 |
| Food and Beverage | $3,197.67 |
| Travel and Lodging | $1,560.40 |
| Consulting Fee | $1,350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,560.40 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $1,916.29 | 2023-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,265.11 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $236.61 | 2023-2025 | Dupixent |
| Amgen INC. | $181.87 | 2024-2025 | Tezspire |
| Insmed, INC. | $180.71 | 2024-2025 | Arikayce, Brinsupri |
| Ethicon INC. | $145.89 | 2023 | Monarch Platform |
| Gilead Sciences, INC. | $135.81 | 2023 | Veklury |
| Abiomed | $133.70 | 2023 | Impella |
| Baxter Healthcare | $114.02 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| La Jolla Pharmaceutical Company | $99.99 | 2023 | Giapreza |
| Otsuka America Pharmaceutical, INC. | $99.90 | 2019 | |
| Paratek Pharmaceuticals, INC. | $94.52 | 2025 | Nuzyra |
| Medtronic, INC. | $83.47 | 2023 | Solitaire X |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $65.33 | 2024 | Glassia |
| Genzyme Corporation | $57.61 | 2025 | |
| Genentech USA, INC. | $55.25 | 2019 | |
| Verona Pharma, INC. | $53.44 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.47 | 2024-2025 | Ofev |
| Pulmonx Corporation | $36.69 | 2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Novartis Pharmaceuticals Corporation | $29.51 | 2025 | |
| Pharming Healthcare, INC. | $29.51 | 2023 | Ruconest |
| Mylan Specialty L.P. | $28.76 | 2023 | Yupelri |
| United Therapeutics Corporation | $24.84 | 2023 | Tyvaso |
| Inogen, INC. | $22.90 | 2023 | Inogen |
| Abbvie INC. | $22.67 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.67 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.